LIPIROS

This brand name is authorized in Nigeria.

Active ingredients

The drug LIPIROS contains one active pharmaceutical ingredient (API):

1	Rosuvastatin UNII 83MVU38M7Q - ROSUVASTATIN CALCIUM
	Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.
	Read more about Rosuvastatin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-4600	Tablet	LIPIROS TABLET TAB 10 mg 1 X 30	33 RNW-PP-208857 LIPIROS TABLET ROSUVASTAIN 10MG ROSUVASTATIN 10MG B4-4600 Drugs Imported Products 1X30 Prescription Only Medicine (POM) 4/21/2023 MALVEN MEDICS INTERNATIONAL COMPANY LTD, WILMER STREET, ILUPEJU ILUPEJU LAGOS 8037205003 malvenmedics@yahoo.com M/S West Coast Pharmaceutical Works Ltd., NO,17 & 16/5,MELDI ESTATE,NEAR PRASANG PARTY PLOT,OPP.SOLA BHAGWAT,SAYONA CITY ROAD,GOTA,AHMEDABAD 382481,GUJARAT,INDIA., India	25/09/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AA07	Rosuvastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-4600